Fosravuconazole for onychomycosis

NewsBot · May 10, 2024

Members do not see these Ads. Sign Up.
Long-term follow-up study of the efficacy of fosravuconazole in the treatment of onychomycosis in elderly patients
Ayaka Okubo et al
J Dermatol. 2024 May 3

Onychomycosis is a chronic and intractable disease whose prevalence increases during aging. In elderly patients, if onychomycosis is left untreated and progresses to a severe stage it may cause functional decline of the lower limbs due to foot pain. This could lead to a decline in activities of daily living and secondary impairment such as cognitive decline. Thus, the treatment of onychomycosis in elderly patients is important. We have previously shown that fosravuconazole is relatively safe and effective for onychomycosis in elderly patients. In the present study, we continued the follow-up study and investigated the efficacy of re-administration of fosravuconazole in patients with recurrent onychomycosis. One hundred and twenty-five patients aged ≥65 years who had been initially diagnosed with onychomycosis at our hospital's dermatology department, and who had responded well to fosravuconazole at 48 weeks after the initial treatment, were followed up until 144 weeks after the start of the initial treatment. Patients who experienced a recurrence within 24 weeks after the start of the follow-up were assigned to the short-term recurrence group, and those who experienced a recurrence after 24 weeks were assigned to the long-term recurrence group. All patients in both groups were re-treated with fosravuconazole to evaluate its efficacy. The short-term and long-term recurrence groups consisted of 17 (14.3%) and 10 (8.4%) patients, respectively. There were no significant differences in mean age and sex ratio between the two groups. There were no serious adverse effects in either group, and the toenail opacity ratio was significantly reduced after 12 weeks of re-treatment in both groups. The short-term and long-term recurrence groups were significantly more likely to have wedge-shaped onychomycosis and total dystrophic onychomycosis, respectively. The results suggest that re-administration of fosravuconazole is safe and as effective as the first administration for elderly patients with recurrent onychomycosis.
Click to expand...

NewsBot · May 10, 2024

Fosravuconazole

Chemical compound

Fosravuconazole (trade name Nailin) is a triazole antifungal agent.^[1]^[2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail.^[3] It is a prodrug that is converted into ravuconazole.^[1]
Drugs for Neglected Diseases Initiative (DNDi) and the Japanese pharmaceutical company Eisai found that fosravuconazole works as a treatment for mycetoma, a serious condition.^[1]^[4]^[5] The Phase II clinical trial found that oral fosravuconazole was safe, patient-friendly, and effective in treating eumycetoma.^[6]^[7] Eumycetoma mainly affects young adults in poorer, rural areas; the standard treatment is itraconazole, which is much more expensive at about US$2,000 for a year than fosravuconazole and unaffordable, and not available in all endemic countries.^[7]

^ ^a ^b ^c Yamaguchi H (2016). "Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis". Medical Mycology Journal. 57 (4): E93–E110. doi:10.3314/mmj.16-00006. PMID 27904057.

^ "Fosravuconazole - Seren Pharmaceuticals". Adis Insight. Springer Nature Switzerland AG.

^ "Oral Antifungal Agent Nailin Capsules 100 mg Approved in Japan" (Press release). Eisai. January 19, 2018.

^ "Fosravuconazole". Drugs for Neglected Diseases Initiative. 23 November 2023 [Project started in 2015; updated in 2023 with results of the Phase II clinical trial].

^ "Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma" (Press release). Eisai Co., Ltd. 10 September 2015.

^ "World's first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment" (Press release). Drugs for Neglected Diseases initiative (DNDi). 23 November 2023.

^ ^a ^b Johnson, Sarah (23 November 2023). "Cheap over-the-counter nail drug found to work on crippling flesh-eating disease". The Guardian. The head of mycetoma at the DNDi labelled the discovery 'momentous', and said 'We were all very excited, it's going to be a gamechanger'.

Read More

Fosravuconazole for onychomycosis

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Fosravuconazole

Recommendation for Onychomycosis prophylaxis, post nail avulsion ?

Assessment of Visual Diagnosis by Podiatrists for HPV and Onychomycosis:

Inactivation of Dermatophytes Causing Onychomycosis and Its Therapy Using Non-Thermal Plasma

Google Search Trends in Onychomycosis

Trace Elements in Serum and Toenail Samples of Patients with Onychocryptosis and Onychomycosis

Lacuna method of treatment for onychomycosis

Glycolic acid peel for onychomycosis

Share This Page

Fosravuconazole for onychomycosis

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Fosravuconazole

Recommendation for Onychomycosis prophylaxis, post nail avulsion ?

Assessment of Visual Diagnosis by Podiatrists for HPV and Onychomycosis:

Inactivation of Dermatophytes Causing Onychomycosis and Its Therapy Using Non-Thermal Plasma

Google Search Trends in Onychomycosis

Trace Elements in Serum and Toenail Samples of Patients with Onychocryptosis and Onychomycosis

Lacuna method of treatment for onychomycosis

Glycolic acid peel for onychomycosis

Share This Page

Useful Searches